Skip to main content

Table 5 Exacerbations outcomes in tiotropium and placebo groups according to different threshold criteria for bronchodilator responsiveness.

From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

 

Tiotropium

Placebo

Hazard (or Rate) Ratio (95%CI) (tiotropium/placebo)

p-value

Patients with ≥1 exacerbation, n (%)

Responsiveness Criterion A

    

   Nonresponder

913 (67.3)

946 (67.9)

0.86 (0.79, 0.94)

0.0014

   Responder

1021 (67.2)

1036 (68.5)

0.86 (0.79, 0.94)

0.0008

Responsiveness Criterion B

    

   Nonresponder

634 (63.7)

676 (67.6)

0.85 (0.76, 0.95)

0.0029

   Responder

1300 (69.1)

1306 (68.5)

0.87 (0.80, 0.94)

0.0003

Responsiveness Criterion C

    

   Nonresponder

1198 (67.7)

1204 (67.5)

0.89 (0.82, 0.96)

0.0036

   Responder

736 (66.4)

778 (69.3)

0.82 (0.74, 0.91)

0.0002

Number of exacerbations/patient year, mean

Responsiveness Criterion A

    

   Nonresponder

0.76

0.87

0.87 (0.79, 0.95)

0.0019

   Responder

0.69

0.82

0.85 (0.78, 0.92)

0.0002

Responsiveness Criterion B

    

   Nonresponder

0.65

0.77

0.84 (0.75, 0.94)

0.0026

   Responder

0.76

0.88

0.86 (0.80, 0.93)

0.0001

Responsiveness Criterion C

    

   Nonresponder

0.74

0.86

0.86 (0.79, 0.93)

0.0001

   Responder

0.70

0.81

0.86 (0.77, 0.95)

0.0025

  1. p-value and hazard ratio based on Cox-regression for analysis of time to first exacerbation. p-value and rate ratio based on Poisson-regression with adjustment for overdispersion for analysis of number of exacerbations per patient year.